The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Abstract
BACKGROUND: Disturbances of N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission may play an important role in the pathophysiology of negative symptoms of schizophrenia. Glycine, a small nonessential amino acid, functions as an obligatory coagonist at NMDA receptors through its action at a strychnine-insensitive binding site on the NMDA receptor complex. Glycine-induced augmentation of NMDA receptor-mediated neurotransmission may thus offer a potentially safe and feasible approach for ameliorating persistent negative symptoms of schizophrenia. METHODS: Twenty-two treatment-resistant schizophrenic patients participated in a double-blind, placebo-controlled, 6-week, crossover treatment trial with 0.8 g/kg per day of glycine added to their ongoing antipsychotic medication. Clinical assessments, including the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), the Simpson-Angus Scale for Extrapyramidal Symptoms, and the Abnormal Involuntary Movement Scale, were performed biweekly throughout the study. Clinical laboratory values and amino acid serum levels were monitored. RESULTS: Glycine treatment was well tolerated and induced increased glycine (P=.001) and serine (P=.001) serum levels. Glycine administration resulted in (1) a significant (P<.001) 30%+/-16% reduction in negative symptoms, as measured by the PANSS, and (2) a significant (P<.001) 30%+/-18% improvement in the BPRS total scores. The improvement in negative symptoms was unrelated to alterations in extrapyramidal effects or symptoms of depression. Low pretreatment glycine serum levels significantly predicted (r= 0.80) clinical response. CONCLUSION: These findings support hypoglutamatergic hypotheses of schizophrenia and suggest a novel approach for the pharmacotherapy of negative symptoms associated with this illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1978) · Biochemical Education · doi:10.1016/0307-4412(78)90049-3 · Cited by 5,046
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,422
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Muir, K. W., & Lees, K. R. (1995) · Stroke · doi:10.1161/01.str.26.3.503 · Cited by 502
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Five-Factor Model of Schizophrenia Initial Validation
LINDENMAYER, J.-P., BERNSTEIN-HYMAN, R., & GROCHOWSKI, S. (1994) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199411000-00006 · Cited by 258
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
Self-citationD-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
Nyberg, S., Farde, L., Halldin, C., Dahl, M., & Bertilsson, L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.173 · Cited by 143
Chemotherapy in psychiatry : principles and practice
Baldessarini, R. J. (1985) · Medical Entomology and Zoology · Cited by 135
Breese, C. R., Freedman, R., & Leonard, S. S. (1995) · Brain Research · doi:10.1016/0006-8993(94)01384-t · Cited by 134
Ishimaru, M. J., Kurumaji, A., & Toru, M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91197-5 · Cited by 115
Perry, T. L. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90212-9 · Cited by 112
Rison, R. A., & Stanton, P. K. (1995) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00017-8 · Cited by 102
Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia
Rosse, R. B., Theut, S. K., Banay‐Schwartz, M., Leighton, M. P., Scarcella, E., Cohen, C. G., & Deutsch, S. I. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198910000-00006 · Cited by 101
Glycine Therapy of Schizophrenia
Waziri, R. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90093-5 · Cited by 100
Antagonism of phencyclidine-induced hyperactivity by glycine in mice
Tóth, E., & Lajtha, Á. (1986) · Neurochemical Research · doi:10.1007/bf00965013 · Cited by 95
Leiderman, E. A., Zylberman, I., Zukin, S. R., Cooper, T. B., & Javitt, D. C. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00585-4 · Cited by 92
Self-citationExcitatory Amino Acid Receptors in Schizophrenia
Ułas, J., & Cotman, C. W. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.1.105 · Cited by 89
Cerebrospinal fluid amino acid concentrations in chronic schizophrenia
Korpi, E. R., Kaufmann, C. A., Marnela, K., & Weinberger, D. R. (1987) · Psychiatry Research · doi:10.1016/0165-1781(87)90095-3 · Cited by 74
Gattaz, W. F., Gasser, T., & Beckmann, H. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90038-1 · Cited by 74
Differences between antipsychotic drugs in persistence of brain levels and behavioral effects
Cohen, B. M., Tsuneizumi, T., Baldessarini, R. J., Campbell, A., & Babb, S. M. (1992) · Psychopharmacology · doi:10.1007/bf02245121 · Cited by 61
COSTA, J., Khaled, E., Sramek, J. J., Bunney, W. E., & Potkin, S. G. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199002000-00027 · Cited by 57
Glycine Site Agonists of the NMDA Receptor: A Review
D’Souza, D. C., Charney, D. S., & Krystal, J. H. (1995) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1995.tb00285.x · Cited by 56
Heresco‐Levy, U., Silipo, G. S., & Javitt, D. (1996) · PubMed · Cited by 53
Self-citationNyberg, S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220079011 · Cited by 51
Cited by
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Metadata
- Authors
- Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-01-01
- Volume
- 56
- Issue
- 1
- Pages
- 29
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2022180773
- Cited by
- 487
- References
- 35
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.